EvoPAR-Prostate01: AZD5305 vs placebo in men with mCSPC

Who Can Participate in the Study?

Age Group
Adults

Study Details

Full Title
A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician's Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)
Principal Investigator
Headshot of Jeffrey William Shevach
Assistant Professor of Medicine
Protocol Number
IRB: PRO00114544
NCT: NCT06120491
Phase
Phase III
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL